Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

GSK Forms Vaccine JV with Jiangsu Walvax

publication date: Oct 6, 2009

GlaxoSmithKline has formed a JV with Jiangsu Walvax Biotech Company to develop and manufacture pediatric vaccines for the China market. Initially, the JV will be funded with $65.6 million of capital, of which $32 million (65%) will come from GSK. The JV will begin operations by producing Priorix™, GSK’s pediatric vaccine for measles, mumps and rubella (MMR). The JV will build a new manufacturing facility, and it plans to extend its operations to include other pediatric vaccines over time. More details...

Stock Symbol: (NYSE: GSK)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital